Mereo BioPharma Group plc PDMR Shareholding (1029U)
20 Novembro 2019 - 11:31AM
UK Regulatory
TIDMMPH
RNS Number : 1029U
Mereo BioPharma Group plc
20 November 2019
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR Dealing
London, November 20, 2019 - Mereo BioPharma Group plc (AIM: MPH,
NASDAQ: MREO), a clinical stage UK based biopharmaceutical company
focused on rare diseases, received notification that on November
19, 2019, Alastair Mackinnon, Chief Medical Officer of Mereo,
purchased 12,879 Ordinary Shares at a price of GBP0.39 per share.
On the same day, Alastair also purchased 4930 American Depositary
Shares (ADS) at a price of USD2.60 per ADS.
The below announcement and notification is made in accordance
with the EU Market Abuse Regulation. The form required under the EU
Market Abuse Regulation follows.
1 Details of the person discharging managerial responsibilities
a) Name Alastair Mackinnon
------------------------ ------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------
a) Position/status Chief Medical Officer
------------------------ ------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------
a) Description of MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
the financial
instrument, type
of instrument
and identification
code
------------------------ ------------------------------------------
b) Nature of the PURCHASE
transaction
------------------------ ------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBP0.39 12879
----------
------------------------ ------------------------------------------
d) Aggregated information: Aggregated volume: 12879
volume, Price Aggregated price: GBP0.386
------------------------ ------------------------------------------
e) Date of the transaction 2019-11-19
------------------------ ------------------------------------------
f) Place of the AIMX
transaction
------------------------ ------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Alastair Mackinnon
------------------------ --------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Medical Officer
------------------------ --------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ --------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ --------------------------------------------------
b) Nature of the PURCHASE
transaction
------------------------ --------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) USD2.60 4930
----------
------------------------ --------------------------------------------------
d) Aggregated information: Aggregated volume: 4930
volume, Price Aggregated price: USD2.60
------------------------ --------------------------------------------------
e) Date of the transaction 2019-11-19
------------------------ --------------------------------------------------
f) Place of the XNMS
transaction
------------------------ --------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBSBDBIDDBGCG
(END) Dow Jones Newswires
November 20, 2019 09:31 ET (14:31 GMT)
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025